Treatment guidelines: latest news

Treatment guidelines resources

Treatment guidelines features

Treatment guidelines news from aidsmap

More news

Treatment guidelines news selected from other sources

  • HIV Treatment Guidelines Nix Atripla as First-Line Therapy

    A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antiretrovirals.

    09 April 2015 | AIDSMeds
  • WHO issues its first hepatitis B treatment guidelines

    WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries.

    12 March 2015 | World Health Organization
  • Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3

    The TEMPRANO study presented as a late breaker oral presentation, included important information for timing of TB prophylaxis and the timing of ART in TB-endemic countries. The conclusions though do not support universally starting treatment at CD4 counts >500 or answer the primary question of the international START study.

    03 March 2015 | HIV i-Base
  • HIV Positive Guys Need To Consider Going On Meds Earlier — ACON

    MORE HIV-positive men need to think about starting treatment straight after diagnosis if ambitious targets to end HIV transmission by 2020 are to be met, the head of New South Wales based LGBTI health body ACON has said. The comments come as the organisation launches a major new sexual health campaign that also aims to clear up confusion surrounding one of the newest buzzwords in the HIV lexicon: "undetectable".

    23 February 2015 | Star Observer
  • HIV Organizations Urge Continuation of D:A:D Study

    D:A:D follows 50,000 HIV-positive people, looking at drug safety and side effects over time. Results from D:A:D have changed HIV treatment guidelines, and how HIV-positive people are treated by their health care providers. We urge pharmaceutical companies to continue funding this vital study.

    11 February 2015 | Treatment Action Group
  • Zimbabwe finally switches away from stavudine

    The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.

    19 January 2015 | AllAfrica
  • Dolutegravir and Truimeq approved in England: London guidelines updated

    On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

    14 January 2015 | HIV i-Base
  • Study uncovers new ground about when to start HIV therapy

    A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.

    13 January 2015 | CATIE
  • Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

    Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

    12 January 2015 | The Institute for Quality and Efficiency in Health Care
  • First Year After HIV Infection Is Key Window for Treatment Start

    Waiting to start HIV treatment until 12 months after the estimated date of seroconversion decreases the likelihood of restoring the immune system.

    07 January 2015 | AIDSMeds
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also